Dave Lashmet of Stensberry Ventures is out with a new teaser ad about a new clinical phase drug that is being developed by a ting biotech company that will literally change the world. Some of the teaser statements that hint to the company are:
The biotech firm developing this drug is a tiny startup that consists of about 50 employees, most of them scientists. It doesn’t have the resources to produce, market and sell a blockbuster drug on its own.
Lashmet’s announcement concerns the final clinical trial results of a drug so revolutionary, it’s the only one of its kind — and promises to cure a disease that kills more people than HIV and tuberculosis combined.
The drug that Dave Lashmet is touting is one that is designed to fight antibiotic-resistant bacteria.
This disease is caused by a class of pathogens that the Director of the U.S. CDC says could “devastate our economy” and kill millions.
The Phase 2 for this company’s new revolutionary drug showed a 100% success rate and Phase 3 results are expected in 90 Days.
Does this sound familiar to anyone?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.